

Juan C Hernández-Boluda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4449367/publications.pdf>

Version: 2024-02-01

158
papers

4,711
citations

109311

35
h-index

123420

61
g-index

162
all docs

162
docs citations

162
times ranked

4687
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of donor-derived CD34 ⁺ infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2022, 57, 261-270.	2.4	9
2	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplantation, 2022, 57, 416-422.	2.4	11
3	Second versus first wave of COVID-19 in patients with MPN. Leukemia, 2022, 36, 897-900.	7.2	7
4	How I manage myeloproliferative neoplasm unclassifiable: Practical approaches for 2022 and beyond. British Journal of Haematology, 2022, , .	2.5	2
5	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. Leukemia Research, 2022, 115, 106821.	0.8	3
6	Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. Cancer, 2022, 128, 2441-2448.	4.1	14
7	Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT. British Journal of Haematology, 2022, , .	2.5	0
8	Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. Cancers, 2022, 14, 2331.	3.7	2
9	SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology and Oncology, 2022, 15, 54.	17.0	26
10	An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with tyrosine kinase inhibitors. Expert Review of Hematology, 2022, , 1-8.	2.2	3
11	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. British Journal of Haematology, 2022, 198, 785-789.	2.5	2
12	Impact of molecular profiling on the management of patients with myelofibrosis. Cancer Treatment Reviews, 2022, 109, 102435.	7.7	2
13	Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. Leukemia, 2021, 35, 215-224.	7.2	34
14	Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. Leukemia, 2021, 35, 623-627.	7.2	12
15	Cytoreductive treatment in patients with CALR mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. British Journal of Haematology, 2021, 192, 988-996.	2.5	8
16	Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2021, 96, 69-79.	4.1	40
17	European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. Current Research in Translational Medicine, 2021, 69, 103267.	1.8	12
18	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia, 2021, 35, 485-493.	7.2	70

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. <i>Blood Cancer Journal</i> , 2021, 11, 16.	6.2	29
20	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	6.2	26
21	Thiotepa+busulfan+fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1593-1602.	2.4	8
22	The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. <i>Leukemia and Lymphoma</i> , 2021, 62, 2040-2043.	1.3	7
23	Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , 2021, 2, 236-248.	1.0	4
24	Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1944-1952.	2.4	7
25	Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2160-2172.	2.4	25
26	Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2021, 35, 2445-2459.	7.2	36
27	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	6.2	9
28	Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , 2021, 96, 1186-1194.	4.1	17
29	Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Journal of Clinical Medicine</i> , 2021, 10, 3146.	2.4	10
30	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology</i> , 2021, 8, e658-e665.	4.6	17
31	CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , 2021, 69, 103304.	1.8	12
32	The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , 2020, 55, 431-440.	2.4	13
33	An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2020, 209, 15-21.	4.8	8
34	Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , 2020, 22, e13206.	1.7	13
35	Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 358-366.	2.0	36
36	Clinical significance of <i>Pneumocystis jirovecii</i> DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , 2020, 80, 578-606.	3.3	2

#	ARTICLE	IF	CITATIONS
37	Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 152-158.	0.2	3
38	Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 23, e13507.	1.7	7
39	Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2237-2244.	2.0	14
40	Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2251.	2.4	12
41	Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , 2020, 61, 1823-1832.	1.3	1
42	Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , 2020, 22, e13440.	1.7	4
43	P0623ACUTE RENAL FAILURE IN HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION. TWO GRAFT VS HOST DISEASE (GVHD) PROFILAXIS PROTOCOL COMPARISON. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
44	Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 2147-2159.	2.4	24
45	Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2020, 22, e13301.	1.7	7
46	Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1347-1356.	2.4	9
47	Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. <i>Leukemia Research</i> , 2020, 91, 106338.	0.8	12
48	Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , 2020, 99, 791-798.	1.8	17
49	miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. <i>Leukemia</i> , 2020, 34, 2648-2659.	7.2	18
50	Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 972-977.	2.0	11
51	Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. <i>Annals of Hematology</i> , 2020, 99, 527-537.	1.8	11
52	Características clínico-biológicas de los pacientes con mielofibrosis: un análisis de 1.000 casos del Registro Español de Mielofibrosis. <i>Medicina Clínica</i> , 2020, 155, 152-158.	0.6	3
53	Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2020, 55, 1493-1496.	2.4	2
54	Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , 2019, 54, 90-98.	2.4	12

#	ARTICLE	IF	CITATIONS
55	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , 2019, 98, 2319-2328.	1.8	13
56	Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , 2019, 21, e13158.	1.7	17
57	Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2167-2171.	2.0	69
58	Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. <i>Frontiers in Oncology</i> , 2019, 9, 603.	2.8	90
59	Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , 2019, 19, 2479-2494.	4.7	45
60	Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. <i>Anticancer Research</i> , 2019, 39, 4757-4766.	1.1	3
61	Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , 2019, 208, 405-414.	4.8	3
62	Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , 2019, 78, 393-401.	3.3	17
63	Spontaneously resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , 2019, 91, 1128-1135.	5.0	3
64	Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against <i>Candida</i> spp. and <i>Aspergillus</i> spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 740-747.	2.0	5
65	Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 1894-1903.	5.8	36
66	Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1510-1512.	4.0	2
67	Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2019, 98, 321-330.	1.8	21
68	Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 94, 22-27.	1.8	5
69	Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1022-1030.	2.0	11
70	Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , 2018, 53, 787-790.	2.4	5
71	Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , 2018, 90, 1375-1382.	5.0	3
72	Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , 2018, 18, 2885-2894.	4.7	22

#	ARTICLE	IF	CITATIONS
73	Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , 2018, 97, 813-820.	1.8	7
74	Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , 2018, 67, 805-807.	5.8	12
75	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2018, 8, 25.	6.2	26
76	Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , 2018, 181, 397-400.	2.5	34
77	Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 563-570.	2.0	31
78	Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. <i>Mycoses</i> , 2018, 61, 206-212.	4.0	15
79	Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , 2018, 8, 91.	6.2	38
80	Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , 2018, 20, e12926.	1.7	24
81	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018, 105, 139-143.	2.1	2
82	Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , 2018, 90, 1438-1443.	5.0	15
83	Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , 2018, 67, 814-819.	1.8	2
84	Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , 2017, 102, 103-109.	3.5	52
85	Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. <i>Neurological Sciences</i> , 2017, 38, 1213-1221.	1.9	40
86	A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1177-1185.	2.0	22
87	Impact of cytomegalovirus <sc>DNA</sc>emia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , 2017, 19, e12717.	1.7	18
88	A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. <i>Transplant Infectious Disease</i> , 2017, 19, e12729.	1.7	17
89	Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2017, 178, 764-771.	2.5	22
90	When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?. <i>Bone Marrow Transplantation</i> , 2017, 52, 1448-1451.	2.4	4

#	ARTICLE	IF	CITATIONS
91	Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , 2017, 98, 407-414.	2.2	23
92	A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. <i>PLoS ONE</i> , 2017, 12, e0173532.	2.5	6
93	Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 2017, 5, 162-174.	1.2	3
94	Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2016, 96, 285-290.	2.2	17
95	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , 2016, 30, 2032-2038.	7.2	75
96	Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. <i>Transplant Infectious Disease</i> , 2016, 18, 89-92.	1.7	10
97	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016, 101, 926-931.	3.5	118
98	Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , 2016, 6, e493-e493.	6.2	80
99	Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. <i>British Journal of Haematology</i> , 2016, 172, 786-793.	2.5	60
100	Alleviating anemia and thrombocytopenia in myelofibrosis patients. <i>Expert Review of Hematology</i> , 2016, 9, 489-496.	2.2	13
101	Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. <i>Annals of Hematology</i> , 2016, 95, 719-732.	1.8	5
102	Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , 2016, 57, 120-124.	1.3	16
103	Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , 2015, 94, 1791-1796.	1.8	57
104	Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , 2015, 94, 911-918.	1.8	49
105	BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. <i>Leukemia Research</i> , 2015, 39, 1278-1284.	0.8	7
106	Target hematologic values in the management of essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , 2015, 94, 4-11.	2.2	16
107	Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. <i>Journal of Medical Economics</i> , 2014, 17, 435-441.	2.1	8
108	JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events. <i>American Journal of Hematology</i> , 2014, 89, 517-523.	4.1	40

#	ARTICLE	IF	CITATIONS
109	BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia. <i>Cancer Cell</i> , 2014, 26, 428-442.	16.8	292
110	Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , 2014, 93, 2037-2043.	1.8	66
111	The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , 2014, 99, e55-e57.	3.5	51
112	Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. <i>Annals of Hematology</i> , 2013, 92, 771-775.	1.8	26
113	Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. <i>British Journal of Haematology</i> , 2013, 161, 865-871.	2.5	27
114	A polymorphism in the <i>TYMP</i> gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2013, 88, 883-889.	4.1	7
115	A polymorphism in the <i>XPD</i> gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , 2012, 119, 5221-5228.	1.4	37
116	Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. <i>Blood</i> , 2012, 119, 1363-1369.	1.4	198
117	Polymyositis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , 2012, 96, 386-389.	1.6	9
118	Functional polymorphisms in <i>SOCS1</i> and <i>PTPN22</i> genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2012, 36, 174-181.	0.8	17
119	Absence of mutations in the activation loop and juxtamembrane domains of <i>VEGFR-1</i> and <i>VEGFR-2</i> gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , 2012, 36, e50-e51.	0.8	0
120	An <i>XRCC1</i> polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , 2011, 52, 1249-1254.	1.3	6
121	Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2011, 152, 81-88.	2.5	72
122	Correlation between genetic polymorphisms of the <i>hOCT1</i> and <i>MDR1</i> genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , 2011, 35, 1014-1019.	0.8	52
123	Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection. <i>Bone Marrow Transplantation</i> , 2011, 46, 1484-1486.	2.4	8
124	Reconstitution of CMV pp65 and IE-1-specific IFN- γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2011, 46, 1437-1443.	2.4	59
125	Prognostic Factors in Classic Myeloproliferative Neoplasms. , 2011, , 85-96.		0
126	Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , 2010, 95, 1317-1324.	3.5	53

#	ARTICLE	IF	CITATIONS
127	Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , 2010, 116, 1205-1210.	1.4	202
128	<i>XPC</i> genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , 2010, 85, 482-486.	4.1	26
129	Kinetics of cytomegalovirus (CMV) pp65 and IE-specific IFN γ CD8 ⁺ and CD4 ⁺ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection. <i>Journal of Medical Virology</i> , 2010, 82, 1208-1215.	5.0	31
130	Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN γ CD8 ⁺ and CD4 ⁺ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2010, 45, 543-549.	2.4	53
131	An Assessment of the Effect of Human Herpesvirus-6 Replication on Active Cytomegalovirus Infection after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 653-661.	2.0	33
132	Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. <i>Leukemia Research</i> , 2009, 33, 589-592.	0.8	3
133	Prognostic factors in chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 343-353.	1.7	15
134	Quantification of DNA in Plasma by an Automated Real-Time PCR Assay (Cytomegalovirus PCR Kit) for Surveillance of Active Cytomegalovirus Infection and Guidance of Preemptive Therapy for Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3311-3318.	3.9	109
135	Enumeration of cytomegalovirus-specific interferon γ CD8 ⁺ and CD4 ⁺ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. <i>Haematologica</i> , 2008, 93, 1434-1436.	3.5	49
136	JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. <i>Haematologica</i> , 2007, 92, 1717-1718.	3.5	51
137	Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , 2007, 21, 143-150.	7.2	167
138	Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. <i>Leukemia</i> , 2007, 21, 1218-1223.	7.2	112
139	Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , 2006, 134, 184-186.	2.5	67
140	Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. <i>Bone Marrow Transplantation</i> , 2005, 36, 847-853.	2.4	47
141	Survivin expression in the progression of chronic myeloid leukemia: A sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , 2005, 46, 717-722.	1.3	26
142	Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. <i>British Journal of Haematology</i> , 2004, 127, 399-403.	2.5	125
143	Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis. <i>Experimental Hematology</i> , 2003, 31, 204-210.	0.4	39
144	Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 120, 500-504.	2.5	9

#	ARTICLE	IF	CITATIONS
145	Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. <i>Haematologica</i> , 2003, 88, 1117-22.	3.5	26
146	Idiopathic Myelofibrosis Associated with Primary Biliary Cirrhosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 673-674.	1.3	11
147	Imatinib mesylate (Gleevec(R)/Glivec(R)): A new therapy for chronic myeloid leukemia and other malignancies. <i>Drugs of Today</i> , 2002, 38, 601.	2.4	31
148	Allogeneic transplantation of CD34+selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?. <i>Blood</i> , 2001, 98, 2352-2357.	1.4	71
149	Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , 2001, 80, 516-520.	1.8	7
150	Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , 2001, 66, 324-327.	2.2	26
151	Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2000, 65, 104-108.	2.2	30
152	Blast Crisis of Ph-Positive Chronic Myeloid Leukemia with Isochromosome 17q: Report of 12 Cases and Review of the Literature. <i>Leukemia and Lymphoma</i> , 2000, 38, 83-90.	1.3	21
153	Non-Hodgkin's Lymphoma Following Untreated Essential Thrombocythemia. <i>Leukemia and Lymphoma</i> , 2000, 36, 421-423.	1.3	7
154	Danazol treatment of idiopathic myelofibrosis with severe anemia. <i>Haematologica</i> , 2000, 85, 595-9.	3.5	51
155	Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. <i>Leukemia</i> , 1999, 13, 150-154.	7.2	205
156	Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. <i>Haematologica</i> , 1999, 84, 26-31.	3.5	11
157	Treatment of elderly patients with AML: results of an individualized approach. <i>Haematologica</i> , 1998, 83, 34-9.	3.5	6
158	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	1